Breaking News, Collaborations & Alliances

Isis Earns Biogen Milestone

Advances Phase III Evaluation of SMNRx

By: Kristin Brooks

Managing Editor, Contract Pharma

Isis Pharmaceuticals, Inc. has earned a $9 million milestone payment from Biogen Idec related to advancing the Phase III study evaluating ISIS-SMNRx in infants with spinal muscular atrophy (SMA). 
 
The ENDEAR study will evaluate the efficacy and safety of a 12 mg dose of ISIS-SMNRx with a primary endpoint of survival or time to permanent ventilation in approximately 110 infants diagnosed with SMA. 

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters